Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000803 · ClinicalTrials.gov registry record · Phase 2
A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 471
- Enrollment target
NCT00000803: Completed Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000803 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 471 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (254% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000803, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 471 participants
- Enrollment target
Study Summary
To determine the safety and anti-HIV activity of delavirdine mesylate ( U-90152 ) in combination with zidovudine ( AZT ) and/or didanosine ( ddI ) versus AZT/ddI combination. U-90152 has demonstrated anti-HIV activity. Since the combination of this drug with either AZT or ddI has synergistic inhibitory activity against HIV-1 in vitro, and triple therapy appears to have greater inhibitory activity against HIV-1 in vitro than dual therapy, the use of U-90152 in combination with AZT and/or ddI may improve the benefits of these drugs in persons with HIV disease.
Interventions
- DRUG Zidovudine
- DRUG Didanosine
- DRUG Delavirdine mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 471 participants |
| Est. Completion | 1997-03 |
| Phase | Phase 2 |
What the finished NCT00000803 record still lists
NCT00000803 is an interventional study that assigns participants to a tested intervention. The registered 471 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (254% higher).
The record links to 0 conditions, and to 3 interventions - of which Zidovudine is the first listed.
NCT00000803 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000803 about?
NCT00000803 is a clinical study titled "A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy". To determine the safety and anti-HIV activity of delavirdine mesylate ( U-90152 ) in combination with zidovudine ( AZT ) and/or didanosine ( ddI ) versus AZT/ddI combination. U-90152 has demonstrated anti-HIV activity. Since the combination of this drug with either AZT or ddI has synergistic inhibi...
What is the current status of trial NCT00000803?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 471 participants. Estimated completion is 1997-03.
What interventions are being tested in trial NCT00000803?
The interventions under investigation include: Zidovudine (DRUG), Didanosine (DRUG), Delavirdine mesylate (DRUG).
Who is sponsoring clinical trial NCT00000803?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00000803's enrollment target sits among peer trials
471 78th of 2000 higher than 1,923 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03010150 · 471 participants
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
- NCT05201404 · 471 participants · Phase 3
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
- NCT06375083 · 472 participants · Phase 2
Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression
- NCT06947187 · 472 participants · NA
Vaccine Confidence and Infodemic in Southeast Asia's Nusantara Sociocultural Sphere